The United States Food and Drug Administration (FDA) approved the combination of PD-L1 inhibitor atezolizumab with BRAF inhibitor vemurafenib plus MEK inhibitor cobimetinib for the first-line treatment of advanced melanoma patients with BRAFV600 mutations in 2020. The gene discussed is BRAF; the disease is melanoma.